NCT00486434

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,176 (actual)
• Sponsor: Nordic Bioscience A/S · Industry
• Sex: All
• Age: 51 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoarthritis of the knee.

Conditions

• Osteoarthritis

Interventions

Type	Name	Description
DRUG	SMC021 Oral Calcitonin	0.8mg SMC021 (Oral Calcitoinin) twice daily
DRUG	SMC021 Placebo	Placebo orally, twice daily

Timeline

• Start date: 2007-05-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2007-06-14
• Last updated: 2019-04-26
• Results posted: 2012-06-28

Locations

9 sites across 6 countries: Czechia, Denmark, Estonia, Hong Kong, Poland, Romania